Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
The Union Cabinet on 12 May 2021 approved the Production-Linked Incentive (PLI) Scheme "National Programme on Advanced Chemistry Cell (ACC) Battery Storage" with a Rs 18,100 crore (~USD 2.4 bn) outlay over five years to build 50 GWh of ACC and 5 GWh of "Niche" ACC manufacturing capacity in India. Selected bidders receive PLI cash incentives over five years on sale of cells made in India, gated on minimum 25% domestic value addition rising to 60% by year five and chemistry-agnostic eligibility (Li-ion, Na-ion, solid-state, flow, lead-acid). The MHI awarded the first 50 GWh tranche on 24 March 2022 (Hyundai Global Motors 20 GWh, Ola Electric 20 GWh, Reliance New Energy Solar 5 GWh, Rajesh Exports 5 GWh) under a QCBS global tender; the Hyundai Global Motors award was withdrawn after Hyundai Motor Company disowned the bidder in August 2022, triggering a re-tender of the orphaned capacity that completed in 2025.
The Department of Pharmaceuticals notified the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) on 21 July 2020 via Gazette Notification, with an outlay of Rs 6,940 crore (~USD 920m) over FY 2020-21 to FY 2027-28. The scheme covers 41 identified critical bulk-drug products across four target segments — fermentation-based (Key Fermentation; Niche Fermentation) and chemical synthesis-based (Key Chemical Synthesis; Niche Chemical Synthesis) — paying 20% incentive on incremental sales for fermentation-based products (years 1-4) tapering to 15% (year 5) and 5% (year 6), and a flat 20% over 5 years for chemically-synthesised products. The stated objective is to reduce India's ~70% bulk-drug import dependence on China by establishing greenfield domestic manufacturing capacity with at least 90% domestic value addition for fermentation products and 70% for chemical-synthesis products.